AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06525194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: An Interprofessional Education Program Based on the ARCS-V Motivation Model on the Theme of Chronic Disease Management and Patient Safety
Study NCT04876196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selfapy for Bulimia Nervosa
Description: Web-based intervention for Bulimia Nervosa with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
Study NCT05684926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation yoga
Description: Yoga consists of bodily postures or poses called asanas, breathing practices called pranayama, and meditation sections that provide focus. Children's yoga aims to teach pre-school (3-6 years) and school (7-12 years) children to breathe correctly, to practice yoga postures using their imaginations, to preserve their existing body flexibility and to teach correct posture. It consists of compositions such as postures, breathing exercises, imitations of living things in nature, memory games. They also relax with the pranayama breathing exercises done during the session. It aims to develop children's creativity through relaxation exercises, moving poses and stories told. Children's yoga also serves an artistic aspect with activities such as listening to music, singing, rhythm games, and drawing.
Study NCT05232578 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Early salvage radiotherapy (eSRT)
Description: eSRT administered immediately after the confirmation of the biochemical relapse (PSA ≈ 0.2ng/ml).~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy.
Study NCT05232578 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Delayed Salvage radiotherapy (dSRT)
Description: dSRT administered if PSA levels increase to ≥ 0.4 ng/ml.~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy.
Study NCT05598437 — intervention group
Intervention type: DEVICE
Intervention: Dry eye device
Description: Dry eye analysis
Study NCT06355739 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CAR T cell injection
Description: intravenous injection
Study NCT06358573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT230-6
Description: INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate.~The IMP is without marketing authorization in Switzerland and anywhere in the world.
Study NCT06358573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neoadjuvant immuno-chemotherapy
Description: Standard of care
Study NCT06358573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neoadjuvant immuno-chemotherapy
Description: Standard of care
Study NCT06202833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture with regulating immunity as the core of treatment
Description: The patient was supine, the acupuncture points were disinfected with 75% ethanol, and the acupuncture points on the head and neck were first acupuncture, and then the acupuncture points on the abdomen and limbs. baihui: When the 1.5 inch millimeter needle is needled, the tip of the needle and the acupoint are at a 15-30 ° Angle, and the needle is about 1 inch flat along the subcutaneous area. The twisting speed is about 200 times per minute, and the stitches are once every 15 minutes, and each stitch is about 30 seconds. zhongwan, tianshu: 1.5 inch needle straight puncture 1 inch, small amplitude lifting and twisting. guanyuan, qihai: 1.5 inch millimeter needle downward oblique puncture 1 inch, small amplitude lifting and twisting. The above acupoints were measured by obtaining qi, and the needles were retained for 30min, once a day.5 days a week for 4 weeks.Twenty days in total.
Study NCT06202833 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Needles that are not on acupoints
Description: In this group, acupuncture treatment was performed at 1cm side of the selected points of the Tongyuan acupoint acupuncture group.The piercing Angle is the same as the test group, only piercing, not twisting.Once a day, 5 days a week for 4 weeks.Twenty days in total.
Study NCT06333587 — intervention group
Intervention type: PROCEDURE
Intervention: image-guided thermal ablation
Description: image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
Study NCT04762368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active anodal tDCS
Description: a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
Study NCT04762368 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham anodal tDCS
Description: The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
Study NCT04857931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
Study NCT04857931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
Study NCT06525324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant surgery with T-PRF and xenograft
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with T-PRF and xenograft will be placed according to the standard protocol.~The surgical wound closure will be coapted with mattress and single interrupted sutures
Study NCT06525324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant surgery with PRF and xenograft
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with PRF and xenograft will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures
Study NCT05668962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Selpercatinib Oral, twice daily during initial treatment period (28 Days). A second course of selpercatinib if the participant is demonstrating clinical benefit to the initial course selpercatinib and deemed clinically appropriate by the treating investigator
Study NCT05668962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Iodine I-131
Description: I-131 NaI, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer
Study NCT05668962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: RhTSH injection, dosage per protocol, timing per protocol during the initial treatment period per standard of care.~Participants may receive a second course of rhTSH if the participant is demonstrating clinical benefit to the initial course rhTSH and deemed clinically appropriate by the treating investigator.
Study NCT06195540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb.~Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment).~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician.
Study NCT06195540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Heparin Molecular Weight
Description: Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician.
Study NCT05905926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study. Doses can be titrated to either 50 mg BID or 25 mg BID
Study NCT05451654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
Study NCT05451654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
Study NCT05952180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality and Cycloergometer
Description: The session performed uses a standard cycloergometer, with the participant pedaling in a seated position with the lower limbs. A 43 inches TV screen is placed in front of the cycloergometer where the participant will watch a video of a walk through a natural environment on. The speed of the walk is linked to the pedaling speed so that the faster the participant pedals, the faster the video goes too. The session last 30 minutes in the participant's room.
Study NCT05952180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard cycloergometer
Description: the session uses usual cycloergometer with the participant pedaling in a seated position with the lower limbs. The session lats 30 minutes in the participant's room.
Study NCT04777500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous electrical nerve stimulation device
Description: We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.
Study NCT05271864 — intervention group
Intervention type: DEVICE
Intervention: Apple Watch
Description: Apple Watch
Study NCT06440291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: Cardioneuroablation procedure performed according to the protocol
Study NCT04530890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Only blood samples at different times of treatment
Study NCT05962788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voclosporin
Description: Subjects will receive 2 capsules (15.8 mg) BID (twice daily), 3 capsules (23.7 mg) BID or 4 capsules (31.6 mg) BID of voclosporin in addition to standard of care with mycophenolate mofetil (MMF) and steroids.
Study NCT05441085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: programed intermittent epidural bolus interval 90 (EI90)
Description: programed intermittent epidural bolus interval 90 (EI90) of 10 ml, 0.0625% bupivacaine plus 2 μg/mL fentanyl
Study NCT05222815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM
Description: Continuous glucose monitor (CGM)-based glucose monitoring
Study NCT05222815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG
Description: Self-monitoring of blood glucose (SMBG)-based glucose monitoring
Study NCT05581186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulse electromagnetic field therapy
Description: It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 25 Hz frequency, 30 Gauss, %35 intensity and for 25 minutes. The treatment period was 5 days a week for 3 weeks, in total. It was applied as 15 sessions.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
Study NCT05581186 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham pulse electromagnetic field therapy
Description: Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 15 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
Study NCT05131880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GAIT RE-EDUCATION PROGRAM ON A SEQUENTIAL MAT IN SUBJECTS WITH PARKINSON'S DISEASE
Description: Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition.
Study NCT05131880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GAIT RE-EDUCATION PROGRAM ON A SEQUENTIAL MAT IN SUBJECTS WITH PARKINSON'S DISEASE
Description: Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition.
Study NCT05581186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Exercise
Description: Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
Study NCT05781659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound elastography guided pleural biopsy
Description: The patients will undergo ultrasound elastography (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
Study NCT05781659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional ultrasound guided pleural biopsy
Description: The patients will undergo traditional ultrasound (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
Study NCT04139564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx headset
Description: EaseVRx is a virtual reality therapy intended to treat chronic pain
Study NCT04139564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active control VR sham program
Description: VR, 2d visual wildlife scenes similar to some EaseVRx content
Study NCT05029375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS® for Preschoolers
Description: P4P is a 16-week manualized social skills treatment program, adapted from an existing empirically supported social skills intervention for young children with autism
Study NCT04767789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NZ-GHMH-01
Description: Each randomized subject will consume 1 capsule daily bringing 100 mg (≥ 2 x 109 CFU) of active ingredient during 16 weeks (from V2 to V5 visits).
Study NCT04767789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each randomized subject will consume 1 capsule with no active ingredient daily during 16 weeks (from V2 to V5 visits).
Study NCT06205589 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ID93 + GLA-SE vaccine
Description: At Step 2 entry, participants will receive one 0.5 mL injection of ID93 + GLA-SE administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
Study NCT06205589 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: At Step 2 entry, participants will receive one placebo injection (sodium Chloride, 0.9%) administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
Study NCT06050850 — intervention group
Intervention type: BEHAVIORAL
Intervention: NOURISH-ALL
Description: Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.
Study NCT06485817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.
Study NCT04549792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Each subject will receive ustekinumab at Baseline (Day 0) and Months 1, 3, 5, 7, 9, and 11. During the LTE, subjects will receive injections every 8 weeks for one year: Month 13, Month 15, Month 17, Month 19, Month 21, and Month 23. Subjects will come back in for a follow-up visit at Month 25 for an end of study visit (no drug administration).
Study NCT05362877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Earplug
Description: Using earplugs to reduce the symptoms of temporomandibular disorder
Study NCT05362877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusal splint
Description: Using occlusal splints to reduce the symptoms of temporomandibular disorder
Study NCT05362877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Applying exercise to reduce the symptoms of temporomandibular disorder
Study NCT06485817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.
Study NCT06485817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pure saline was administered as the placebo condition.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.